Search Within

Heiko Schoder

  1. "Matthew Matasar"
Formats
  1. Meeting Abstract (25)
  2. Journal Article (17)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (43)
  2. Department of Medicine (43)
  3. Hematologic Malignancies, Division of (43)
  4. Lymphoma (43)
  5. Molecular Imaging and Therapy Service (43)
  6. Radiology, Department of (43)

More Groups

People
  1. Matthew Matasar (43)
  2. Andrew Zelenetz (42)
  3. David Straus (40)
  4. Paul Hamlin (37)
  5. Alison Moskowitz (36)
  6. Anita Kumar (36)

More People

Years
  1. 2024 (2)
  2. 2023 (3)
  3. 2022 (4)
  4. 2021 (7)
  5. 2020 (3)
  6. 2019 (4)

More Years

Publications
  1. Blood (20)
  2. Hematological Oncology (5)
  3. Journal of Clinical Oncology (5)
  4. Haematologica (3)
  5. American Journal of Hematology (1)
  6. Annals of Oncology (1)

More Publications

Publishers
  1. American Society of Hematology (21)
  2. American Society of Clinical Oncology (5)
  3. Wiley Blackwell (5)
  4. Ferrata Storti Foundation (3)
  5. American Association for Cancer Research (1)
  6. Elsevier Science, Inc. (1)

More Publishers

Results (43)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R.; Budde, E.; Barr, P. M.; Batlevi, C. L.; Chen, R.; Constine, L. S.; Courtien, A. I.; Dandapani, S. V.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Phase I/IB dose escalation and expansion of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma
    Meeting Abstract

    Batlevi, C.; Hamlin, P.; Matasar, M.; Gerecitano, J.; Drullinsky, P.; Hamilton, A.; Straus, D.; Horwitz, S.; Kumar, A.; Moskowitz, C.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • PET-adapted therapy with brentuximab vedotin and augmented ICE for relapsed/refractory Hodgkin lymphoma - Lack of Improvement with 3 versus 2 cycles of weekly brentuximab vedotin
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Yahalom, J.; Schöder, H.; Barr, P. M.; Caron, P.; Chiu, A.; Constine, L. S.; Drullinsky, P.; Friedberg, J. W.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Prospective study of 3′-deoxy-3′-(18)F-fluorothymidine PET for early interim response assessment in advanced-stage B-cell lymphoma
    Journal Article

    Schoder, H.; Zelenetz, A. D.; Hamlin, P.; Gavane, S.; Horwitz, S.; Matasar, M.; Moskowitz, A.; Noy, A.; Palomba, L.; Portlock, C.; more...
    Journal of Nuclear Medicine (2016)

    Fulltext@MSK | Save
  • Imaging for staging and response assessment in lymphoma
    Journal Article

    Johnson, S. A.; Kumar, A.; Matasar, M. J.; Schöder, H.; Rademaker, J.
    Radiology (2015)

    Fulltext@MSK | Save
  • Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma
    Journal Article

    Sauter, C. S.; Matasar, M. J.; Meikle, J.; Schoder, H.; Ulaner, G. A.; Migliacci, J. C.; Hilden, P.; Devlin, S. M.; Zelenetz, A. D.; Moskowitz, C. H.
    Blood (2015)

    Fulltext@MSK | Save
  • PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: A non-randomised, open-label, single-centre, phase 2 study
    Journal Article

    Moskowitz, A. J.; Schöder, H.; Yahalom, J.; Mccall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Lancet Oncology (2015)

    Fulltext@MSK | Save
  • Safety and early efficacy in an ongoing pilot study of brentuximab vedotin and AVD chemotherapy followed by 30 gray involved-site radiotherapy for newly diagnosed, early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Yahalom, J.; Schoder, H.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; Hamilton, A.; Hamlin, P.; Horwitz, S. M.; Jacob, A. G.; more...
    Blood (2014)

    Fulltext@MSK | Save